期刊
RHEUMATOLOGY
卷 60, 期 9, 页码 4205-4217出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keaa909
关键词
Systemic lupus erythematosus; health-related quality of life; patient-reported outcomes; patient perspective
类别
资金
- GlaxoSmithKline Investigator-Sponsored Studies (ISS) programme
- Swedish Rheumatism Association [R-932236]
- King Gustaf V's 80-year Foundation [FAI-2019-0635]
- Professor Nanna Svartz Foundation [2019-00290]
- Ulla and Roland Gustafsson Foundation [2019-12]
- Region Stockholm and Karolinska Institutet
Overweight and obesity were associated with adverse physical and mental HRQoL outcomes in SLE patients after therapeutic intervention, while underweight was linked to adverse mental HRQoL outcome. Addition of belimumab to standard therapy had a protective effect against adverse general health and severe fatigue.
Objectives To investigate whether abnormal BMI is associated with adverse health-related quality of life (HRQoL) outcome, including severe fatigue, after 52weeks of standard therapy plus belimumab or placebo in patients with SLE. Methods We analysed data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (n=1684). Adverse HRQoL was defined as SF-36 scores <= the fifth percentile in age- and sex-matched US population-based subjects, and FACIT-F scores <30. We compared BMI groups using the Pearson's (2) test, and assessed independence with multivariable logistic regression analysis. Results Overweight (BMI >= 25kg/m(2)) and obese (BMI >= 30kg/m(2)) patients showed increased likelihood to exhibit adverse SF-36 physical component summary (OR: 1.8; 95% CI: 1.4, 2.3; P <0.001 and OR: 2.4; 95% CI: 1.8, 3.2; P <0.001, respectively) and FACIT-F (OR: 1.3; 95% CI: 1.1, 1.6; P = 0.010 and OR: 1.5; 95% CI: 1.2, 2.0; P = 0.002, respectively) scores at week 52. Underweight was associated with adverse SF-36 mental component summary scores, also after adjustment for sex, ancestry, age, disease duration, disease activity, organ damage and prednisone dose during the study period (OR: 2.1; 95% CI: 1.2, 3.6; P = 0.007). Addition of belimumab to standard therapy independently protected against adverse SF-36 general health (OR: 0.8; 95% CI: 0.6, 1.0; P = 0.025) and FACIT-F<30 (OR: 0.8; 95% CI: 0.6, 1.0; P = 0.018). Conclusion Overweight and obesity contributed to adverse physical and mental HRQoL outcomes after therapeutic intervention in SLE patients, and underweight contributed to adverse mental HRQoL outcome. A protective effect of belimumab against adverse general health and severe fatigue was implicated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据